Mallinckrodt PLC (MNK) vs. Repligen Corporation (RGEN) Head to Head Comparison

Mallinckrodt PLC (NYSE: MNK) and Repligen Corporation (NASDAQ:RGEN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.

Profitability

This table compares Mallinckrodt PLC and Repligen Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mallinckrodt PLC 12.64% 15.28% 5.20%
Repligen Corporation 15.61% 9.90% 5.93%

Institutional and Insider Ownership

97.4% of Mallinckrodt PLC shares are held by institutional investors. Comparatively, 96.5% of Repligen Corporation shares are held by institutional investors. 0.8% of Mallinckrodt PLC shares are held by insiders. Comparatively, 1.5% of Repligen Corporation shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Mallinckrodt PLC and Repligen Corporation, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mallinckrodt PLC 0 4 13 0 2.76
Repligen Corporation 0 1 3 0 2.75

Mallinckrodt PLC presently has a consensus price target of $59.97, indicating a potential upside of 86.48%. Repligen Corporation has a consensus price target of $46.00, indicating a potential upside of 26.83%. Given Mallinckrodt PLC’s stronger consensus rating and higher probable upside, equities analysts clearly believe Mallinckrodt PLC is more favorable than Repligen Corporation.

Volatility & Risk

Mallinckrodt PLC has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500. Comparatively, Repligen Corporation has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.

Earnings and Valuation

This table compares Mallinckrodt PLC and Repligen Corporation’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Mallinckrodt PLC $3.27 billion 0.96 $666.60 million $4.10 7.84
Repligen Corporation $113.32 million 11.96 $29.54 million $0.51 71.12

Mallinckrodt PLC has higher revenue and earnings than Repligen Corporation. Mallinckrodt PLC is trading at a lower price-to-earnings ratio than Repligen Corporation, indicating that it is currently the more affordable of the two stocks.

Summary

Mallinckrodt PLC beats Repligen Corporation on 9 of the 14 factors compared between the two stocks.

About Mallinckrodt PLC

Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.

About Repligen Corporation

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.

Receive News & Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply